PLETHICO

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on November 09, 2012, inter alia, consider the following :- (1) Acceptance of Resignation of Mr. Abhay Suhane, Independent Non-Executive Director of the Company, who has resigned from the Board of Directors of the Company on October 03, 2012; (2) Appointment of Mr. Hitesh Thakar as an Additional Director (Independent Non-Executive).

Plethico Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2012.

IDBI Trusteeship Services Limited has submitted to the Exchange vide its letter dated November 05, 2012 a copy of Disclosure under Regulation 29(1)/ 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Shashikant Patel has submitted to the Exchange vide its letter dated October 05, 2012 a copy of disclosure under Regulation 29(2) and 31(1)&(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Shashikant Patel has submitted to the Exchange, vide letter dated September 14, 2012, a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shashikant Patel has submitted to the Exchange, vide letter dated September 04, 2012, a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shashikant Patel has submitted to the Exchange, vide letter dated August 17, 2012, a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Arum Investments Private Limited has submitted to the Exchange, vide letter dated August 11, 2012 a copy of Disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shashikant Patel has submitted to the Exchange, vide letter dated August 14, 2012, a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Plethico Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended June 30,2012 with Limited Review Report.

Plethico Pharmaceuticals Limited has informed the Exchange regarding the Outcome of the meeting of the Securities Issue and Allotment Committee of the Board of Directors of the Company held on August 13, 2012.

Plethico Pharmaceuticals Limited has informed the Exchange regarding the Outcome of Annual General Meeting of the Company held on June 29, 2012 and 35A of the Listing Agreement.

Plethico Pharmaceuticals Limited has informed the Exchange regarding the details of the voting results at the Annual General Meeting held on June 29, 2012.

Shashikant A. Patel has submitted to the Exchange, vide letter dated June 19, 2012, a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Plethico Pharmaceuticals Limited has informed the Exchange that Register of Members and Share Transfer Books of the Company will be closed from June 27, 2012 to June 29, 2012 (both days inclusive) for the purpose of Annual General Meeting.

Shashikant Patel has submitted to the Exchange, vide letter dated June 04, 2012, a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Plethico Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2012 alongwith the Limited Review Report.

Shashikant Patel has submitted to the Exchange, vide letter dated April 18, 2012, a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shashikant Patel has submitted to the Exchange, vide letter dated April 03, 2012, a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shashikant Patel has submitted to the Exchange, vide letter dated March 02, 2012, a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors regret their inability to recommend any dividend for the year ended December 31, 2011, given the Global Financial Scenario and also the impending outcome of the FCCB issued by the Company.

Plethico Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2011.

Shashikant Patel has submitted to the Exchange a copy of declaration under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shashikant Patel has submitted to the Exchange a copy of Intimation under Regulation 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shashikant A. Patel has submitted to the Exchange a copy of Intimation under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shashikant Patel has submitted to the Exchange a copy of Revised Intimation under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Plethico Pharmaceuticals Limited has informed the Exchange vide its letter dated January 06, 2012 regarding a press release dated January 04, 2012 of the Company's wholly owned subsidiary Natrol Inc., USA.

Shashikant Patel has submitted to the Exchange a copy of Intimation under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shashikant Patel has submitted to the Exchange a copy of Intimation under Regulation 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

PLETHICO : Plethico Pharmaceuticals Limited has informed the Exchange vide its letter dated November 17, 2011 regarding a press release, titled ."Natrol Partners With Bikram Yoga to introduce Vedic Mantra Ayurvedic Nutritional Supplements".

Plethico Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2011.

Shashikant Patel has submitted to the Exchange a copy of Disclosure under Regulation 31(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Arum Investments Private Limited has submitted to the Exchange a copy of Disclosure under Regulation 29(1) of SEBI ( Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Plethico Pharmaceuticals Limited has submitted to the Exchange a copy of the Proceedings of the Annual General Meeting of the Company held on September 28, 2011.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on August 12, 2011, inter-alia considered the following: (1) Fixing September 28, 2011 for holding the Annual General Meeting of the members of the Company for the accounting year ended December 31, 2010. (2) The Register of Members and Share Transfer Books would remain closed from September 26, 2011 to September 28, 2011 (both days inclusive) for the purpose of distribution of dividend to the members for the accounting year ended December 31, 2010.

Plethico Pharmaceuticals Limited has informed the Exchange vide its letter dated August 16, 2011, regarding a press release dated August 13, 2011, titled "Plethico Pharmaceuticals announces Q2 FY 2011 Results".

Plethico Pharmaceuticals Limited has informed the Exchange that the Ministry of Corporate Affairs, New Delhi ("MCA") has taken the "Green Initiative in the Corporate Governance" vide Circular No. 17/2011 dated April 21, 2011 and Circular No.18/2011 dated April 29, 2011 allowing paperless compliances by companies through electronic mode. Companies are now permitted to send all communications/documents including the Notice calling the General Meeting (including AGM), audited financial statements, directors' report, auditors' report etc. through electronic mode to their shareholders. Further, the

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors in their meeting held on June 03, 2011 had decided to defer the Annual General Meeting to a future date and given their consent to file application with the Registrar of Companies, Madhya Pradesh & Chhattisgarh for seeking extension of time for convening Annual General Meeting of the Company for the financial year ended on December 31, 2010 for a further period of 3 months. Further the Company has informed that Application was made to ROC for extension of AGM and the Registrar of Companies, Madhya Pradesh &

Plethico Pharmaceuticals Limited has informed the Exchange that Mr. Rajiv Bedi, President and Mr. Hemant Modi, Chief Operating Officer of the Company have resigned from the Company w.e.f. April 30, 2011 and May 31, 2011, respectively. Hence they have ceased to be KMPs of the Company under the said designation.

Plethico Pharmaceuticals Limited has informed the Exchange regarding the proceedings of Extra-Ordinary General Meeting of the members of the Company held on June 03, 2011.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on June 03, 2011, has decided to defer the Annual General Meeting to a future date and for which the Company has filed an application to the Registrar of Companies, Madhya Pradesh & Chhattisargh, Gwalior for the extension of Annual General Meeting for a further period of 3 months under Section 166 of the Companies Act 1956.

Plethico Pharmaceuticals Limited has informed the Exchange vide its letter dated May 17, 2011, regarding a press release dated May 14, 2011, titled "Plethico Pharmaceuticals announces Q1 FY 11 Results".

Plethico Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2011.

Plethico Pharmaceuticals Limited has submitted to the Exchange a copy of Notice of an Extra-ordinary General Meeting of the Members of the Company to be held on June 03, 2011.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on April 13, 2011, has considered the options of managing the liabilities of the company through various initiatives such as amending the terms and conditions of the outstanding Foreign Currency Convertible Bonds Issued on October 2007("FCCBs), including but not limited to tenor, interest rate, yield to maturity, other methods of extinguishing FCCBs, including and not limited to repurchase, redemption, buyback, either wholly, partly or in tranches etc., or restructuring of

Plethico Pharmaceuticals Limited has submitted to the Exchange vide its letter dated April 13, 2011 a copy of Corporate Presentation of the Company.

Plethico Pharmaceuticals Limited had informed the Exchange regarding press release for the audited financial results of the Company for quarter and accounting year ended on December 31, 2010. The Company has now submitted to the Exchange a copy of Addendum to Press Release for the audited financial results for the quarter and accounting year ended December 31, 2010.

Plethico Pharmaceuticals Limited has informed the Exchange vide its letter dated April 04, 2011, regarding a Revised press release dated March 31, 2011, titled "Plethico Pharmaceuticals announces FY 2010 Results".

Plethico Pharmaceuticals Limited has informed the Exchange vide its letter dated April 01, 2011, regarding a press release dated March 31, 2011, titled "Plethico Pharmaceuticals announces FY 2010 Results".

Plethico Pharmaceuticals Limited has informed the Exchange that the Baord of Directors of the Company at its meeting held on March 31, 2011 recommended dividend @ 25 % i.e. Rs. 2.50 per equity share of the Company.